> Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Reshma L. Mahtani, DO

general_content

Event details

Understanding your breast cancer diagnosis, treatment, and potential side effects can be overwhelming. In this video, Reshma L. Mahtani, DO, answers questions about breast cancer treatment options, recent drug approvals, immunotherapy, as well as symptoms and side effects for early stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer.

video

audio_embed

speakers_feature

About our expert:

Reshma L. Mahtani, DO

Reshma L. Mahtani, DO, is a medical oncologist practicing in South Florida. She is an associate professor of medicine at the University of Miami, Sylvester Comprehensive Cancer Center in Deerfield Beach, Florida. She is co-leader of the breast cancer program and director of community outreach.

Read full bio

upcoming_events

Upcoming Events

Navigating the changing landscape of early-stage breast cancer

Wed, May 14, 2025

Learn More

Newsflash: Updates from the 2025 ASCO Annual Meeting

Thu, Jun 12, 2025

Learn More

2025 Butterfly Ball

Sat, Nov 08, 2025

Learn More

View All Events View Past Events

related_resources_article_carousel

Datopotamab deruxtecan

04/02/25 | BY: Sara Hurvitz

Datopotamab deruxtecan (Datroway) is approved to treat hormone receptor-positive, HER2-negative metastatic breast cancer. It is an antibody-drug conjugate, a treatment that delivers chemotherapy directly to cancer cells.

| 6 Min. Read

Hormone receptor-positive MBC

04/02/25 | BY: Pallav K. Mehta

Learn more about hormone receptor-positive metastatic breast cancer, which means the stage IV breast cancer is hormone-sensitive.

| 6 Min. Read | 1

Tamoxifen

02/23/25 | BY: Reshma L. Mahtani, Brooke Worster

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

| 11 Min. Read | 8

Targeted therapy for hormone receptor-positive breast cancer

02/21/25 | BY: Sameer Gupta, Pallav K. Mehta

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy, including CDK 4/6 inhibitors.

| 12 Min. Read | 1

Trastuzumab deruxtecan

01/31/25 | BY: Pallav K. Mehta

Trastuzumab deruxtecan (Enhertu or T-DXd) is an antibody-drug conjugate that treats HER2-positive, HER2-low, or HER2-ultralow breast cancer that cannot be removed surgically or that has spread to another part of the body.

| 4 Min. Read

Inavolisib

12/11/24 | BY: Rita Nanda

Inavolisib (Itovebi) is a new targeted therapy shown to reduce progression of certain hormone receptor-positive, HER2-negative, PIK3CA-positive metastatic breast cancers.

| 8 Min. Read | 1

FISH tests

11/15/24 | BY: Regina Hampton

A FISH test is a lab test performed on tissue taken from a biopsy or breast cancer surgery, that can confirm breast cancer’s HER2 status if other test results are inconclusive.

| 5 Min. Read

Immunohistochemistry (IHC) tests

11/15/24 | BY: Regina Hampton

Some of the most important breast cancer treatment decisions are based on immunohistochemistry (IHC) tests; hormone receptor status, HER2 status, and in some cases, PD-L1 status.

| 7 Min. Read

Ribociclib

09/18/24 | BY: Sameer Gupta

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

| 6 Min. Read | 1

Early-stage breast cancer trial search

06/21/24

Use this tool to find early-stage breast cancer clinical trials across the United States.

| 1

stay_connected

Stay Connected

FIRST NAME* LAST NAME*

EMAIL ADDRESS*

I HAVE / HAVE HAD BREAST CANCER. I'M AT HIGH RISK FOR BREAST CANCER. I CARE ABOUT SOMEONE WITH BREAST CANCER. I WORK WITH PATIENTS WITH BREAST CANCER. OTHER